TELA Bio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TELA | ELUT | ARX.AX | XTNT | SVS.MI | OFIX | |
|---|---|---|---|---|---|---|
| Market cap | 37.82M | 33.64M | 171.82M | 41.53M | 41.69M | 392.90M |
| P/E (TTM) | — | — | 49.0 | — | 6.2 | — |
| Forward P/E | -1.8 | -0.7 | 16.8 | -9.9 | 5.8 | 26.3 |
| Price/book | -2.4 | 2.1 | 2.1 | 1.0 | 0.6 | 0.9 |
| Dividend yield | — | — | — | — | 2.50% | — |
| 1-year change | −28.98% | −19.32% | −38.22% | −62.03% | −20.00% | −33.79% |
| Today | +4.46% | −6.59% | +1.03% | +6.47% | 0.00% | +10.96% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 20 min.
Latest news
All TELA news ›Malvern’s TELA Bio Receives FDA 510(k) Clearance for Liora™ Monofilament Scaffold, Its First In-House Developed Implant
TELA Bio , a Malvern, Pennsylvania-based commercial-stage medical technology company focused on soft tissue reconstruction, announced on October 5, 2026 that the U.S. Food and Drug Administration has granted 510(k) clearance for its Liora™…
TELA Bio Wins FDA Clearance for Resorbable Surgical Mesh
MALVERN, PA — TELA Bio Inc. (NASDAQ: TELA) has received U.S. Food and Drug Administration clearance for a fully resorbable surgical mesh developed and manufactured at its Malvern facility, expanding the medical technology company’s…
TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript
TELA Bio, Inc. (TELA) Shareholder/Analyst Call October 8, 2026 10:00 AM EDT Greetings, and welcome to the TELA Bio, Inc. Virtual Special Meeting. [Operator Instructions]. Please note, this conference is being recorded. I will now turn the…
TELA Bio regains Nasdaq minimum bid price compliance
TELA common stock continues to be listed and traded on the Nasdaq Global Market under the ticker TELA. TELA Bio, Inc. regained compliance with the Nasdaq Global Market’s minimum bid price requirement for continued listing under Nasdaq…
More from 1 other outlet
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S.…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net2
- biobuzz.io1
- kalkinemedia.com1
- manilatimes.net1
- mychesco.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.